About Clostridium Diagnostics
Clostridium is a gram-positive bacteria that belongs to the Firmicutes phylum. There are multiple species of Clostridium — Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, and Clostridium sordellii, which are responsible for numerous infections. Clostridium tetani is responsible for tetanus, Clostridium botulinum causes botulism, Clostridium perfringes leads to gas gangrene, Clostridium sortellii causes pneumonia, endocarditis, arthritis, peritonitis, and myonecrosis, and Clostridium difficile is responsible for diarrhea.
Technavio’s analysts forecast the global clostridium diagnostics market to grow at a CAGR of 14.71% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global clostridium diagnostics market for 2017-2021. To calculate the market size, the report considers the sales/volume/value.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Clostridium Diagnostics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Abbott
• Beckman Coulter
• Olympus
• Siemens Healthineers
• F. Hoffmann-La Roche
Other prominent vendors
• BD
• bioMerieux
• Chrono-log Corporation
• Corgenix
• Diazyme Laboratories
• FUJIREBIO DIAGNOSTICS
• Hologic
• QIAGEN
• Sysmex Corporation
• Thermo Fisher Scientific
Market driver
• Rising prevalence of Clostridium-related diseases
• For a full, detailed list, view our report
Market challenge
• High cost of molecular diagnostics over immunoassays
• For a full, detailed list, view our report
Market trend
• Technological advancements
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Market segmentation by technology
• Immunoassays
• Molecular diagnostics
PART 07: Market segmentation by product
• Clostridium difficile
• Clostridium perfringens
• Clostridium botulinum
• Clostridium tetani
• Clostridium sordellii
PART 08: Market segmentation by end-user
• Hospitals
• Independent laboratories
• Physicians' clinics
PART 09: Geographical segmentation
• Market overview
• Americas
• EMEA
• APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Technological advancements
• Increasing focus on reducing nosocomial infections
• Growing popularity of portable POCT products
PART 13: Vendor landscape
• Competitive landscape
PART 14: Key vendor analysis
• Abbott
• Beckman Coulter
• Olympus Corporation
• Siemens Healthineers
• F. Hoffmann-La Roche
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Global Clostridium diagnostics market: Overview
Exhibit 02: Human pathogenic Clostridium species
Exhibit 03: Global Clostridium diagnostics market 2016-2021 ($ millions)
Exhibit 04: Five forces analysis
Exhibit 05: Global Clostridium diagnostics market by technology 2016 (%)
Exhibit 06: Global immunoassays market: Overview
Exhibit 07: Global Clostridium diagnostics market by immunoassays 2016-2021 ($ millions)
Exhibit 08: Diagnostic tests for Clostridium difficile
Exhibit 09: Global molecular diagnostics market: Overview
Exhibit 10: Global Clostridium diagnostics market by molecular diagnostics 2016-2021 ($ millions)
Exhibit 11: FDA-approved nucleic acid-based tests for diagnosis of Clostridium difficile
Exhibit 12: Global Clostridium difficile diagnostics market 2016-2021 ($ millions)
Exhibit 13: Global Clostridium perfringens diagnostics market 2016-2021 ($ millions)
Exhibit 14: Global Clostridium botulinum diagnostics market 2016-2021 ($ millions)
Exhibit 15: Global Clostridium tetani diagnostics market 2016-2021 ($ millions)
Exhibit 16: Global Clostridium sordellii diagnostics market 2016-2021 ($ millions)
Exhibit 17: Global Clostridium diagnostics market by geography 2016 (%)
Exhibit 18: Global Clostridium diagnostics market by geography 2021 (%)
Exhibit 19: Global Clostridium diagnostics market by geography 2016-2021 ($ millions)
Exhibit 20: Global Clostridium diagnostics market by geography 2016-2021 (%)
Exhibit 21: Clostridium diagnostics market in Americas ($ millions)
Exhibit 22: Clostridium diagnostics market in US: Overview
Exhibit 23: Clostridium diagnostics market in EMEA ($ millions)
Exhibit 24: Clostridium diagnostics market in Germany: Overview
Exhibit 25: Clostridium diagnostics market in APAC ($ millions)
Exhibit 26: Clostridium diagnostics market in Japan: Overview
Exhibit 27: Abbott: Key highlights
Exhibit 28: Abbott: Strength assessment
Exhibit 29: Abbott: Strategy assessment
Exhibit 30: Abbott: Opportunity assessment
Exhibit 31: Beckman Coulter: Key highlights
Exhibit 32: Beckman Coulter: Strength assessment
Exhibit 33: Beckman Coulter: Strategy assessment
Exhibit 34: Beckman Coulter: Opportunity assessment
Exhibit 35: Olympus Corporation: Key highlights
Exhibit 36: Olympus Corporation: Strength assessment
Exhibit 37: Olympus Corporation: Strategy assessment
Exhibit 38: Olympus Corporation: Opportunity assessment
Exhibit 39: Siemens Healthineers: Key highlights
Exhibit 40: Siemens Healthineers: Strength assessment
Exhibit 41: Siemens Healthineers: Strategy assessment
Exhibit 42: Siemens Healthineers: Opportunity assessment
Exhibit 43: F. Hoffmann-La Roche: Key highlights
Exhibit 44: F. Hoffmann-La Roche: Strength assessment
Exhibit 45: F. Hoffmann-La Roche: Strategy assessment
Exhibit 46: F. Hoffmann-La Roche: Opportunity assessment
